Dominique Bron
About
In The Last Decade
Dominique Bron
292 papers receiving 11.4k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Genetics 4.6k
- Oncology 3.8k
- Pathology and Forensic Medicine 3.4k
- Molecular Biology 2.6k
- Immunology 2.2k
Countries citing papers authored by Dominique Bron
This map shows the geographic impact of Dominique Bron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominique Bron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominique Bron more than expected).
Fields of papers citing papers by Dominique Bron
This network shows the impact of papers produced by Dominique Bron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominique Bron. The network helps show where Dominique Bron may publish in the future.
Co-authorship network of co-authors of Dominique Bron
This figure shows the co-authorship network connecting the top 25 collaborators of Dominique Bron. A scholar is included among the top collaborators of Dominique Bron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominique Bron. Dominique Bron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 13 | |
| 4 | 2 | |
| 5 | 47 | |
| 6 | 3 | |
| 7 | 6 | |
| 8 | 82 | |
| 9 | Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study | 2 |
| 10 | Microrna-29c and 223 and Their Prognostic Value in Chronic Lymphocytic Leukemia | 1 |
| 11 | Monoclonal antibody fluorescence for blasts detection, quantification and lineage identification with an automated hematology analyser Abbott-CELL-DYN Sapphire: comparison with flow cytometry and morphology | 1 |
| 12 | 35 | |
| 13 | Recombinant urate oxidase (Rasburicase) is safe and effective in managing hyperuricemia in children and adults: Results of a multi-national compassionate use trial. | 2 |
| 14 | Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884 | 6 |
| 15 | Molecular evidence of a GVL effect in allogeneic transplant for acute lymphoblastic leukemia restricted to Ph-negative leukemia: Post-transplant immuno-modulation performed according to molecular follow-up seems efficient only in this subset of patients | 2 |
| 16 | Fatigue et qualité de vie chez le patient cancéreux | 1 |
| 17 | 9 | |
| 18 | 1 | |
| 19 | A phase I clinical trial of recombinant human interleukine-6 (rhIL-6) in solid tumors | 1 |
| 20 | Déficit en prolidase. A propos d'un cas particulier. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.